# Thymosin Alpha-1

> Thymosin Alpha-1 is a 28-amino-acid peptide fragment derived from prothymosin alpha, naturally produced by the thymus gland. It is marketed in several countries (as Zadaxin) as an adjunct for chronic viral hepatitis and certain cancers, and has been studied for immune support in immunocompromised patients. Research interest centers on its potential to support T-cell maturation and modulate innate and adaptive immune responses. It is not FDA-approved in the United States, and use outside supervised clinical settings is investigational. This profile is educational only and is not medical advice.

- URL: https://www.lifeconverted.com/peptides/thymosin-alpha-1
- Also known as: Tα1, Zadaxin
- Primary category: Immune & Anti-Aging
- Effectiveness rank: #1 in Immune & Anti-Aging; #1 in Anti-Inflammatory
- Evidence level: Well studied
- Route: Subcutaneous
- Dose range: 800-1,600 mcg
- Dose tiers: low 800 mcg; moderate 1600 mcg; high 1600 mcg
- Half-life: Approximately 2 hours in circulation, though downstream immune effects may persist longer
- Timing: Morning
- Cycle: 4-12 weeks on, 4 weeks off (Often cycled around periods of elevated infection risk or immune stress; continuous long-term use is not well studied)
- Storage: Store lyophilized peptide refrigerated (2-8°C); after reconstitution keep refrigerated and use within 2-4 weeks

## Mechanism of action

Thymosin Alpha-1 interacts with toll-like receptors and modulates dendritic cell maturation, potentially supporting a balanced Th1/Th2 immune response. It appears to support thymocyte differentiation and may enhance natural killer cell and cytotoxic T-lymphocyte activity. It may also help regulate cytokine production, potentially tempering excessive inflammatory signaling while supporting pathogen clearance.

## Reported benefits

- May support immune resilience during chronic infection or immunosuppression
- Studied as an adjunct in some chronic viral hepatitis protocols
- May help modulate cytokine balance during immune dysregulation
- Explored as supportive care alongside certain cancer treatments
- May support vaccine response in some studied populations

## Reported side effects

- Injection site redness or irritation
- Mild flu-like symptoms in some users
- Headache
- Rare hypersensitivity reactions

## Common protocols

- Twice-weekly subcutaneous injections for immune support
- Short-term use during recovery from acute illness

## Stacking notes

Sometimes discussed alongside other immune-supportive peptides such as LL-37 or Thymulin; no established synergy data exists

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer